Ajinomoto OmniChem

What Ajinomoto OmniChem does

Ajinomoto OmniChem is a Belgian-headquartered specialty chemicals and pharmaceutical Contract Development and Manufacturing Organization (CDMO) operating as a wholly-owned subsidiary of Japan's Ajinomoto Co., Inc. (TYO: 2802). The company produces pharmaceutical active pharmaceutical ingredients (APIs) and intermediates — including highly potent APIs at OEB 4/5 containment and cryogenic manufacturing — alongside green fine chemicals, amino acids, tannins, plant-based biostimulants, and Tensiofix surfactants. Its technology base rests on 75 years of botanical extraction, 40 years of organic synthesis, 15 years of biocatalysis, and a 2024-launched proprietary AJIPHASE platform for industrial-scale oligonucleotide manufacturing, supported by two continuous flow chemistry installations at its Wetteren site.

The company operates six production sites across Belgium (Wetteren HQ, Balen, Mont-Saint-Guibert), Spain (Montaverner, Valencia), and India (Visakha/Vizag) — the latter through Granules OmniChem, a 50/50 joint venture with Granules India in which OmniChem took 100% ownership of the Vizag site in 2020 and doubled capacity in 2023. Commercial activity is organized through four sub-brands launched or formalized in 2024: Ajinomoto Bio-Pharma Services (pharmaceutical CDMO), Ajinomoto Agro Solutions (biostimulants), Ajinomoto Sustainable Solutions (green chemistry), and Ajinomoto Amino Acid Solutions (amino acid applications).

The business model is project-based contract manufacturing sold through direct enterprise sales, with pricing that is quote-based and project-specific rather than published. Customers are primarily pharmaceutical companies requiring scalable API and intermediate manufacturing, with secondary demand from agrochemical, nutrition/health/beauty, and specialty chemicals buyers. The company holds GMP (FAMHP), J-SOX, ISO 14001/45001/9001/50001, FSSC 22000, HACCP, and Ecovadis certifications, operates Belgium and Spain sites on 100% renewable electricity, and offers an Eco Passport service that quantifies per-process greenhouse gas emissions for customers.

Name

Ajinomoto OmniChem

Legal name

Ajinomoto Omnichem

Website

https://ajinomoto-omnichem.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Ajinomoto OmniChem is a Belgian CDMO and subsidiary of Ajinomoto Co., Inc. that develops and manufactures pharmaceutical APIs and intermediates, green fine chemicals, amino acids, and plant-based biostimulants across six sites in Belgium, Spain, and India for enterprise pharmaceutical, agrochemical, and specialty chemicals customers.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO and Specialty Chemicals

NAICS

Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411), Pesticide and Other Agricultural Chemical Manufacturing (32532)

SIC

Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Organic & Biological Input Retail (Biostimulants, Biopesticides, OMRI) (AFABAJAK)

Keywords

• Pharmaceutical CDMO services
• Active pharmaceutical ingredients
• Green fine chemicals
• Plant-based biostimulants
• Amino acid solutions

Headquarters

HQ city

Wetteren

HQ country

Belgium

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical APIs and Intermediates CDMO: Contract development and manufacturing services for pharmaceutical active pharmaceutical ingredients and intermediates, including highly potent APIs (HPAPI/OEB 5) and cryogenic manufacturing
2. Green Fine Chemicals: Sustainable chemistry products and custom synthesis services
3. Amino Acids: Amino acid products and solutions for various industries including pharmaceuticals, nutraceuticals, sports nutrition, and health and beauty
4. Tannins and Plant-based Biostimulants: Natural extracts and sustainable agricultural products including gallotannins, biostimulants, and co-formulants
5. Tensiofix Surfactants: Specialty surfactants for industrial applications

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Ajinomoto OmniChem is a Contract Development and Manufacturing Organization (CDMO) that produces and supplies pharmaceutical APIs and intermediates, green fine chemicals, amino acids, tannins, plant-based biostimulants, and Tensiofix surfactants. The company provides custom manufacturing services from pilot to commercial scale, with R&D and production capabilities in organic and green chemistry, extraction technologies, and fermentation. Operations span six manufacturing sites across Belgium, Spain, and India under the Ajinomoto Bio-Pharma Services, Ajinomoto Agro Solutions, Ajinomoto Sustainable Solutions, and Ajinomoto Amino Acid Solutions brands.

Product overview

Ajinomoto Omnichem is a diversified specialty chemicals and pharmaceutical company operating four distinct sub-brands: Ajinomoto Bio-Pharma Services (pharmaceutical CDMO for APIs and intermediates), Ajinomoto Agro Solutions (biostimulants and coformulants for sustainable agriculture), Ajinomoto Sustainable Solutions (green chemistry and custom manufacturing), and Ajinomoto Amino Acid Solutions (amino acid applications). The company also produces Tensiofix® surfactants, offers AJIPHASE® technology for oligonucleotide manufacturing, and provides Eco Passport sustainability assessment services. Operating from 6 manufacturing sites across Belgium, Spain, and India, Ajinomoto Omnichem leverages expertise in organic and green chemistry, extraction technologies, and fermentation to serve pharmaceutical, agricultural, and chemical industries.

Differentiator

Problem solved

Functional benefit

Brands

• Ajinomoto Bio-Pharma Services: Specialized in scaling and producing pharmaceuticals, providing contract development and manufacturing services for APIs and intermediates
• Ajinomoto Agro Solutions
• Ajinomoto Sustainable Solutions
• Ajinomoto Amino Acid Solutions

Products and services

• Ajinomoto Bio-Pharma Services CDMO Contract development and manufacturing organization (CDMO) services for pharmaceutical active pharmaceutical ingredients (APIs) and intermediates, including highly potent APIs (HPAPI/OEB 5), cryogenic manufacturing, and oligonucleotide production via AJIPHASE technology. Scalable solutions from pilot to commercial supply for pharmaceutical companies.
• Ajinomoto Agro Solutions biostimulants and co-formulants Plant-based biostimulants, co-formulants, and gallotannins for sustainable agriculture. Backed by field-validated 30%+ harvest increase outcomes (Kafunjo project, Uganda).
• Ajinomoto Sustainable Solutions green chemistry manufacturing Green fine chemicals, custom synthesis, and sustainable chemical manufacturing services from laboratory to industrial multi-ton scale, leveraging organic synthesis, biocatalysis, and continuous flow chemistry.
• Ajinomoto Amino Acid Solutions Amino acid ingredients and applications for pharmaceuticals, nutraceuticals, sports nutrition, and health and beauty products, leveraging the Ajinomoto Group's amino acid science heritage.
• Tensiofix surfactants Specialty Tensiofix surfactants product line for industrial applications.
• Eco Passport sustainability assessment service Environmental impact assessment service that models greenhouse gas emissions for each process and product, enabling customers to identify more efficient steps and sustainable material alternatives for CSRD and Scope 3 reporting.

Quantifiable outcome

• Increased crop harvest by more than 30% through biostimulant application in Kafunjo project, Uganda
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Forge Biologics Inc.coreStrategic or Co-development Partner · 1 December 2023Ajinomoto Group's acquisition of US-based Forge Biologics Inc. in December 2023 to expand gene therapy CDMO capabilities. This strategic acquisition strengthens Ajinomoto's position in the advanced therapy medicinal products (ATMP) CDMO market and complements Ajinomoto Omnichem's existing pharmaceutical manufacturing capabilities.

Scale indicators6 records

Recent moves16 records

Expansion highlights6 records

Direct peers

• Lonza Group: Global small-molecule API and biologics CDMO with comparable services across APIs, intermediates, HPAPIs and complex modalities — the reference franchise Ajinomoto OmniChem competes with in pharmaceutical CDMO.
• Catalent: Large diversified pharma CDMO offering API, drug-product and biologics services; Ajinomoto Bio-Pharma Services is a directly comparable CDMO franchise within Ajinomoto OmniChem.
• Siegfried Holding: Swiss-listed CDMO focused on small-molecule APIs and drug products, including HPAPIs — directly comparable capacity, customer base and contract development model to Ajinomoto Bio-Pharma Services.
• Hovione: Portugal-headquartered CDMO with strong small-molecule, particle engineering and HPAPI capabilities — closest mid-tier EU peer to Wetteren/Balen site offerings.
• Cambrex: US/EU small-molecule API and intermediates CDMO with HPAPI capacity — directly comparable on contract manufacturing of APIs and intermediates for branded and generic pharma.
• Recipharm: European CDMO providing API and drug-product services (now privately held); directly comparable on CDMO scope and European customer base.
• AGC Pharma Chemicals: Japan-headquartered CDMO with EU (Spain) operations offering APIs, intermediates and oligonucleotide CDMO services — direct competitor in nucleotide synthesis.

Emerging players

• OlON Group: Privately-held Italian API and CDMO with HPAPI capabilities and a focus on generics and oncology — comparable specialty-API CDMO at smaller scale.

Broad incumbents

• Evonik Industries: Diversified specialty chemicals incumbent with amino acids, API CDMO and green chemistry offerings; comparable as a broad-based specialty/CDMO incumbent rather than a focused competitor.

Regional players

• Fareva: French private manufacturer/CDMO of APIs and drug products — directly comparable European CDMO competitor with similar scale and customer profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Ajinomoto-Omnichem
• LinkedInlinkedin.com/company/ajinomoto-omnichem

Compliance14 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ajinomoto OmniChem